Conflict of interest
All authors received grants from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb for the work under consideration for publication. NB reports personal fees from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb for the work under consideration for publication; grants and personal fees from Taiho Pharmaceutical; and grants from Takeda Pharmaceutical, outside the submitted work. TS reports personal fees from Ono Pharmaceutical Co., Ltd., for the work under consideration for publication; other from Ono Pharmaceutical Co., Ltd. (endorsed Department, lecture fee); grants and personal fees and other from Chugai Pharmaceutical and Yakult Honsha (endorsed Department, lecture fee); grants and other from Eli Lilly (lecture fee); grants from MSD, Gilead Sciences, Parexel, Daiichi Sankyo, and Astellas; grants and personal fees from Taiho Pharmaceutical; and personal fees from Takara-Bio, outside the submitted work. M-HR reports honorarium and advisory board fees from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, MSD, Eli Lilly, Taiho Pharmaceutical, Novartis, and Daehwa Pharmaceutical, outside the submitted work. KK reports research funding from Merck & Co., Shionogi & Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD, Merck Serono, and BeiGene, outside the submitted work. HCC reports grants (research support) from Eli Lilly, GlaxoSmithKline, MSD, Merck Serono, Bristol-Myers Squibb, Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical, Amgen, BeiGene, and Incyte; personal fees (honoraria) from Merck Serono, Eli Lilly, Foundation Medicine, and Roche; and personal fees (consultation) from Taiho Pharmaceutical, Celltrion, MSD, Eli Lilly, Quintiles, Bristol-Myers Squibb, Merck Serono, Gloriam, BeiGene, Amgen, and Zymeworks, outside the submitted work. J-SC reports personal fees (consultation) from Ono Pharmaceutical Co., Ltd., for the work under consideration for publication. KMu reports grants and personal fees from Ono Pharmaceutical Co., Ltd., and Sanofi; grants from MSD, Daiichi Sankyo, Parexel International, Shionogi Pharmaceutical, Sumitomo Dainippon Pharma, Pfizer, Mediscience Planning, Solasia Pharma, and Merck Serono; and personal fees from Eli Lilly, Chugai Pharmaceutical, Takeda Pharmaceutical, Taiho Pharmaceutical, Bristol-Myers Squibb, and Bayer, outside the submitted work. K-HY reports personal fees (honoraria) from Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim, Takeda Pharmaceutical, MSD, Eli Lilly, Amgen, and Roche, outside the submitted work. TY reports grants and personal fees (honoraria) from Chugai and Taiho Pharmaceutical; personal fees (honoraria) from Bristol-Myers Squibb, Yakult, Nihon Kayaku, Olympus, Daiichi Sankyo, MSD, and Terumo; and personal fees (honoraria and advisory role) from Ono Pharmaceutical Co., Ltd., Eli Lilly (Japan), Johnson and Johnson, and Covidien, outside the submitted work. TT reports grants from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb for the work under consideration for publication; grants from MDS Pharmaceutical, Merck Serono Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; and grants and personal fees from Daiichi Sankyo Ltd., Takeda Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd., outside the submitted work. K-WL reports grants from Ono Pharmaceutical Co., Ltd., Merck Sharp & Dohme Corp., AstraZeneca/MedImmune, Merck KGaA, Pfizer, BeiGene, ALX Oncology, Zymeworks, MacroGenics, Five Prime Therapeutics, Oncologie, Pharmacyclics, Green Cross Corp, ABLBIO, Y-BIOLOGICS, Genexine, LSK BioPharma, Daiichi Sankyo, and Taiho Pharmaceutical (to his institution for conducting clinical trials); personal fees (honoraria) from Bristol-Myers Squibb, Eli Lilly, and Genexine; and personal fees (consultation) from ISU ABXIS, and Bayer, outside the submitted work. D-YO reports grants from AstraZeneca, outside the submitted work. KMi reports research funding from MSD K.K., Merck Biopharma Co., Ltd., Astellas Pharma Inc., Taiho Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd., outside the submitted work. TN is an employee of Ono Pharmaceutical Co., Ltd. L-TC reports personal fees from Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb for the work under consideration for publication; grants from the Ministry of Science and Technology (Taiwan), Ministry of Health and Welfare (Taiwan); grants, personal fees, and non-financial support from Novartis (study medication and funding support, and honorarium); grants from Pfizer (study funding); personal fees from Eli Lilly (honorarium); grants from Merck Serono (study funding); grants, personal fees, and non-financial support from TTY (study medication and funding support, and honorarium); personal fees from PharmaEngine, Shire, MSD, Bristol-Myers Squibb, and ONO (honorarium); grants from OBI (preclinical testing); grants from Polaris (translational Research funding); grants, personal fees, and non-financial support from SynCore (study medication and funding support, and honorarium); grants and non-financial support from Celgene (study medication and funding); and personal fees from Five Prime and Merrimack, outside the submitted work. Y-KK reports personal fees from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Daehwa Pharmaceutical, Blueprint, Merck, and Astellas, outside the submitted work.